Several breakthroughs demonstrate AI’s growing role in biotechnology: Imperial College London and GSK developed a hybrid machine learning model improving monoclonal antibody design space predictions, enhancing accuracy and reducing experimentation. Researchers at KAIST introduced an AI model for automated optimal drug candidate design targeting cancer mutations. Boston biotech Tahoe Therapeutics raised $30 million to build AI models of living cells for drug discovery.